Eterna Therapeutics Inc. is a preclinical-stage biopharmaceutical company developing induced pluripotent stem cell-derived mesenchymal stem cell (iMSC) therapies for oncology and autoimmune diseases. Its lead program, ERNA-101, is an allogeneic pro-inflammatory cytokine-secreting iMSC designed to reprogram immunosuppressive tumor microenvironments and enhance T-cell anti-tumor activity, targeting solid tumors such as ovarian cancer. ERNA-102 and ERNA-201 focus on anti-inflammatory cytokine delivery for conditions like rheumatoid arthritis and other autoimmune disorders. The company's iMSC platform engineers cells to secrete targeted cytokines directly into tumors or inflamed tissues, addressing unmet needs in cell therapy. Eterna Therapeutics Inc. advances its pipeline through preclinical studies, regulatory engagements including Pre-IND meetings with the FDA, and manufacturing partnerships for clinical-grade production. Founded in 1984 and headquartered in Cambridge, Massachusetts, it leverages mRNA cell engineering technologies to repair cellular dysfunction across therapeutic indications.